Incorporating systems-level stakeholder perspectives into the clinical trial design of school-supervised asthma therapy
Name:
Publisher version
View Source
Access full-text PDFOpen Access
View Source
Check access options
Check access options
Authors
Trivedi, MichelleHoque, Shushmita
Luther, Janki
Spano, Michelle
Shillan, Holly
Pearl, Hallie
Seay, Hannah L.
Phipatanakul, Wanda
Gerald, Lynn B.
Pbert, Lori
Faculty Advisor
Michelle Trivedi, MD, MPHUMass Chan Affiliations
Prevention Research CenterSenior Scholars Program
School of Medicine
Department of Population and Quantitative Health Sciences
Division of Pulmonary Medicine, Department of Pediatrics
Document Type
Journal ArticlePublication Date
2021-09-01Keywords
Childhood asthmaClinical trial design
Implementation
Stakeholder engagement
UMCCTS funding
Clinical Trials
Community-Based Research
Medical Education
Pediatrics
Public Health
Pulmonology
Respiratory Tract Diseases
Metadata
Show full item recordAbstract
RATIONALE: Few evidence-based public health interventions are adopted in practice, in part due to a disconnect between the outcomes measured in clinical trials and the outcomes important to stakeholders that determine implementation in real-world practice. AsthmaLink is a school-supervised asthma therapy program which partners pediatric providers, school nurses, and families. To inform the design of a cluster randomized controlled trial of AsthmaLink, we elicited systems-level stakeholder input. METHODS: Maximum variation sampling was used to recruit 18 stakeholders to participate in semi-structured interviews that were recorded, transcribed, and open coded: Department of Public Health officials (n = 4), school officials (n = 4), pediatric practice managers (n = 3), health insurance officials (n = 4), and legislators (n = 3). Thematic analysis was used to identify common themes related to stakeholder priorities for clinical trial design and perceived barriers to AsthmaLink adoption. RESULTS: Stakeholder groups identified common priorities for the clinical trial design, including examination of the extent to which AsthmaLink (1) reduces health care utilization, (2) is cost effective (2) addresses health disparities, (3) reduces school absenteeism, and (4) educates families about asthma. Stakeholder groups reported potential barriers to AsthmaLink adoption, including challenges pertaining to (1) securing resources, staffing, and reimbursement, (2) variability across school districts, and (3) standing out amidst multiple programs vying for resources. CONCLUSIONS: Systems-level stakeholder input informed refinements to the clinical trial design of a school-supervised therapy program including outcome and implementation measures and choice of study population. Incorporating systems-level stakeholder perspectives into clinical trial design is critical to achieve adoption of evidence-based interventions into practice.Source
Trivedi M, Hoque S, Luther J, Spano M, Shillan H, Pearl H, Seay H, Phipatanakul W, Gerald LB, Pbert L. Incorporating systems-level stakeholder perspectives into the clinical trial design of school-supervised asthma therapy. Contemp Clin Trials. 2021 Sep;108:106510. doi: 10.1016/j.cct.2021.106510. Epub 2021 Jul 16. PMID: 34280575; PMCID: PMC8453113. Link to article on publisher's site
DOI
10.1016/j.cct.2021.106510Permanent Link to this Item
http://hdl.handle.net/20.500.14038/49366PubMed ID
34280575Notes
Shushmita Hoque participated in this study as a medical student in the Senior Scholars research program at the University of Massachusetts Medical School.
Related Resources
ae974a485f413a2113503eed53cd6c53
10.1016/j.cct.2021.106510